Relapsing polychondritis is a rare immune-driven disease in which the body’s own defenses attack cartilage and other tissues rich in a structural protein called proteoglycan, causing repeated bouts of painful inflammation that can permanently deform the ears, collapse the nose, narrow the airways, and damage the eyes and heart. It affects roughly three to four people per million, strikes most often between the ages of 40 and 60, and is notoriously difficult to diagnose because its symptoms mimic dozens of other conditions. Although modern treatment has improved outcomes considerably, the disease remains unpredictable, and the gap between first symptoms and a correct diagnosis can stretch for years.
What the Immune System Attacks and Why
Cartilage is the firm, flexible tissue that gives shape to your ears, tip of your nose, voicebox, windpipe, ribs, and the rings that hold your airways open. In relapsing polychondritis, the immune system generates antibodies that target the collagen proteins forming the scaffolding of that cartilage. Research has found that patients carry autoantibodies against collagen types II, IX, and XI, the major structural collagens that knit cartilage fibers together and anchor them to the surrounding matrix.1PubMed. Autoantibodies to cartilage collagens in relapsing polychondritis The disease is characterized by episodic, progressive inflammation that gradually destroys cartilaginous structures.2PubMed Central. Refractory relapsing polychondritis: challenges and solutions
The trigger for this autoimmune assault is still unclear. A Hungarian national study flagged environmental exposures, including arsenic in drinking water and high sunlight exposure, as possible triggering factors, though these remain hypotheses rather than established causes.3PubMed Central. A nationwide study of the epidemiology of relapsing polychondritis What is well established is that relapsing polychondritis frequently overlaps with other autoimmune disorders. In that same Hungarian cohort, autoimmune co-occurrence was found in 56% of patients, with Sjögren syndrome being the most frequent companion.4PubMed Central. A nationwide study of the epidemiology of relapsing polychondritis
How the Disease Shows Up
The hallmark of relapsing polychondritis is ear inflammation. One or both outer ears turn red, swollen, and painful, sparing the earlobe (which has no cartilage). About 40% of patients present with this symptom at diagnosis, and by the time the disease has run its course, nearly 90% will experience it.5PubMed Central. Early Stage Relapsing Polychondritis Diagnosed by Nasal Septum Biopsy Repeated flares can dissolve the ear cartilage entirely, leaving a floppy, cauliflower-like ear that is one of the most recognizable signs of advanced disease. In a French cohort of 142 patients, auricular chondritis appeared in 96% of cases over time, making it the single most common feature.6PubMed Central. Relapsing polychondritis: clinical presentations, disease activity and outcomes
The nose is the second classic target. Nasal chondritis is present at diagnosis in about a quarter of patients and eventually appears in more than half.7PubMed Central. Early Stage Relapsing Polychondritis Diagnosed by Nasal Septum Biopsy When enough cartilage in the nasal septum is lost, the bridge of the nose collapses inward into what clinicians call a “saddle nose” deformity. Not everyone develops it, but when it appears, it tends to be permanent.
Joint inflammation rounds out the most frequent trio. Arthritis was documented in 54% of the same French cohort, while hearing impairment appeared in 42%, likely from inflammation of the cartilage in the inner ear or middle ear structures.8PubMed Central. Relapsing polychondritis: clinical presentations, disease activity and outcomes Skin involvement, including rashes and nodules, was reported in about 26% of patients.
When It Threatens the Airways
The most dangerous feature of relapsing polychondritis is involvement of the trachea and bronchi, the large tubes that carry air into the lungs. The cartilage rings that hold these airways open can become inflamed, thickened, and eventually weakened to the point of collapse. Tracheobronchial involvement has been reported in roughly 20 to 50% of patients and can be the first symptom that reveals the disease.9PubMed. Tracheobronchial involvement of relapsing polychondritis Symptoms include a barking cough, hoarseness, wheezing, and shortness of breath that can be mistaken for asthma or chronic obstructive pulmonary disease.
In a study of 77 patients with airway involvement, more than half progressed to airway malacia, a condition in which the cartilage becomes so soft that the airway collapses during breathing.10Scientific Reports. Evaluation of airway involvement and treatment in patients with relapsing polychondritis When collapse is severe, airway stents, small mesh tubes placed inside the trachea or bronchi, can be life-saving. Stents maintain the airway’s shape, relieve breathlessness immediately, and can allow patients to return to normal activities.11PubMed Central. Multiple endobronchial airway stents in a case of relapsing polychondritis – A rare entity Other interventions include balloon dilation, tracheostomy, and surgical airway reconstruction. In one early report, placement of multiple metallic stents under conscious sedation prevented life-threatening airway closure in a patient whose other options had been exhausted.12PubMed. Endobronchial stenting for severe airway obstruction in relapsing polychondritis
Eye, Heart, and Other Organ Involvement
About half of all patients develop eye problems at some point. A systematic review found that 49% of patients had ocular involvement, and it was the presenting feature in 21%.13PubMed. The ocular manifestations of relapsing polychondritis The most common issues are scleritis (inflammation of the white of the eye), episcleritis, and uveitis (inflammation inside the eye).14PubMed Central. Ocular Involvement in Relapsing Polychondritis Less frequently, the cornea, retina, optic nerve, or eye-movement muscles can be affected. In a Japanese series of 11 patients, all cases with scleritis were bilateral and recurrent, underscoring how persistent the inflammation can be.15PubMed. Ocular inflammation associated with relapsing polychondritis in Japanese patients: a review of 11 patients
Cardiovascular disease is a less common but potentially deadly complication, historically reported as the second most frequent cause of death in relapsing polychondritis. The most frequent heart-related problems are aortic regurgitation, where the aortic valve leaks blood backward, and aortic aneurysm, a dangerous bulging of the aorta’s wall.16PubMed. Cardiovascular involvement in relapsing polychondritis When valve replacement surgery is needed, the outcomes have historically been sobering: in one review, nearly a quarter of patients needed reoperation within four years due to leakage around the prosthetic valve, a consequence of the disease softening the tissue to which the replacement is anchored.17PubMed. Cardiac valve replacement in relapsing polychondritis. A review
Why Diagnosis Takes So Long
There is no single blood test or imaging scan that confirms relapsing polychondritis. Doctors rely on clinical criteria that look for a combination of features, principally inflammation of the ear cartilage, nasal cartilage, or airway cartilage; joint inflammation; eye inflammation; and hearing or balance problems. Three sets of diagnostic criteria exist (McAdam, Damiani-Levine, and Michet), each with different sensitivity. A study applying all three to a cohort of patients found sensitivities of 50%, 89%, and 67% respectively, meaning some patients with confirmed disease still do not meet the checklist.18PubMed. Observational study and brief analysis of diagnostic criteria in relapsing polychondritis A Polish analysis found that nine out of ten patients met at least one of those three criteria, but the fact that no single set catches everyone highlights why diagnosis remains a clinical judgment call rather than a definitive test.19PubMed Central. Relapsing polychondritis – analysis of symptoms and criteria
The average delay from first symptom to correct diagnosis is measured in years, not months. Part of the problem is that early symptoms, a red ear, a stuffy nose, a sore joint, are common and can easily be attributed to infection, allergy, or run-of-the-mill arthritis. A biopsy of affected cartilage can help, showing the characteristic loss of cartilage matrix and infiltration by immune cells, but biopsy is not always practical or necessary when the clinical picture is clear.
Emerging biomarker research may eventually improve early detection. A recent autoantibody screening study identified antibodies against complement component C4B that tracked with disease activity and decreased as patients moved from flare to remission, while antibodies against keratin 16 predicted recurrence within a year.20Annals of the Rheumatic Diseases. Autoantibody reactome analysis reveals diagnostic biomarkers and molecular classification for relapsing polychondritis These findings are still too new to be used in clinical practice, but they represent genuine progress toward a blood-based diagnostic tool.
The VEXAS Connection
One of the most significant discoveries in the relapsing polychondritis world in recent years is its overlap with a condition called VEXAS syndrome, first described in 2020. VEXAS is caused by a mutation in a gene called UBA1 that occurs not from birth but later in life within blood-forming cells. More than half of patients initially identified as having VEXAS also met the diagnostic criteria for relapsing polychondritis.21PubMed Central. Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS That overlap is not a coincidence: when French researchers screened a cohort of patients who carried both relapsing polychondritis and a bone-marrow disorder called myelodysplastic syndrome, every one of the 21 tested had the UBA1 mutation.22RMD Open. Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients
A Japanese study drove the point further: among male patients with relapsing polychondritis, 73% carried pathogenic UBA1 variants. All of the mutation-positive patients had systemic symptoms, particularly skin lesions.23Annals of the Rheumatic Diseases. Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis The practical takeaway is that male patients diagnosed with relapsing polychondritis, especially those who also have skin problems or abnormal blood counts, should be screened for UBA1 mutations. VEXAS has its own treatment implications and a worse prognosis than typical relapsing polychondritis, so identifying it matters for the decisions that follow.
Treatment Strategy
There is no cure for relapsing polychondritis, and no drug has been approved specifically for it. Treatment aims to control inflammation, prevent cartilage destruction, and spare patients from long-term steroid side effects. French clinical guidelines describe a stepwise approach: start with the lowest effective dose of corticosteroids combined with a conventional immunosuppressant such as methotrexate, azathioprine, or mycophenolate mofetil to keep steroid doses manageable over time.24La Revue de Médecine Interne. Review French practical guidelines for the diagnosis and management of relapsing polychondritis Cyclophosphamide, a more potent immunosuppressant, is reserved for life-threatening disease or when steroids alone cannot hold things in check.25PubMed. Relapsing polychondritis: A 2016 update on clinical features, diagnostic tools, treatment and biological drug use
A systematic review pooling data from published case reports and series provides the best available snapshot of how well various drugs work. Pooled response rates were approximately 72% for abatacept, 66% for tocilizumab, 64% for TNF inhibitors such as infliximab and adalimumab, 56% for methotrexate, 47% for anakinra, and 43% for rituximab.26PubMed. Treatment of relapsing polychondritis: a systematic review These numbers come with substantial uncertainty given the rarity of the disease and the absence of randomized trials, but they give clinicians a rough framework for choosing between options.
Among the biologic drugs, TNF inhibitors are the most frequently prescribed, with infliximab and adalimumab preferred over etanercept.27PubMed. Biologic therapy in relapsing polychondritis: navigating between options A French multicenter study treating 41 patients with 105 biologic courses found an overall response rate of about 63% within the first six months, but complete response was seen in only 19%. Loss of efficacy over time was a real problem, contributing to drug withdrawal in 18% of courses, while infections accounted for most adverse reactions.28Annals of the Rheumatic Diseases. Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study Patients with ear and nose cartilage inflammation tended to respond better to biologics, while those with accompanying myelodysplastic syndrome, now recognized as potential VEXAS, trended toward poorer responses. The response to biologics in this disease is genuinely unpredictable: a review of 62 published cases treated with various biologics found efficacy in 27, partial efficacy in five, and no response at all in 29.29The Journal of Rheumatology. Treatment of Relapsing Polychondritis with Tocilizumab JAK inhibitors are a newer option, but data remain anecdotal.
Survival and Long-Term Damage
Older studies painted a grim picture. A landmark 1986 cohort calculated five- and ten-year survival probabilities of 74% and 55%, with the most common causes of death being infection, systemic vasculitis, and cancer; only 10% of deaths were directly attributable to airway involvement.30PubMed. Relapsing polychondritis. Survival and predictive role of early disease manifestations More recent data are considerably more encouraging. The Hungarian national study found five-year survival in the range of 84 to 93%, comparable to the general population.31PubMed Central. A nationwide study of the epidemiology of relapsing polychondritis An Iranian multicenter study reported a five-year survival of about 96%.32Scientific Reports. A multicenter study of long-term outcomes of relapsing polychondritis in Iran The improvement likely reflects earlier diagnosis, better immunosuppressive regimens, and interventional procedures like airway stenting that simply were not available in the 1980s.
Survival, however, is not the full story. In that Iranian cohort, more than 80% of patients developed measurable disease-related damage despite extensive immunosuppressive treatment. Ear deformity and osteoporosis from long-term steroid use were the most common forms of damage, while tracheobronchial damage, though less frequent, was among the most debilitating.33Scientific Reports. A multicenter study of long-term outcomes of relapsing polychondritis in Iran The disease itself causes harm, and so does the treatment. That tension between suppressing inflammation and avoiding drug toxicity is a central challenge for every patient and doctor managing this condition.
Living With the Disease
Beyond the clinical metrics, relapsing polychondritis takes a heavy toll on daily life that standard health questionnaires struggle to capture. A qualitative study gathering input from hundreds of patients identified personal relationships, work capacity, and activities of daily living as the three areas most frequently affected. About a quarter of respondents described specific problems that existing quality-of-life tools miss entirely, such as difficulty planning ahead because of unpredictable flares, impaired verbal communication from airway or laryngeal involvement, and the frustration of not being taken seriously by people around them.34PubMed Central. Identifying quality of life domains and facets affected in relapsing polychondritis: a qualitative analysis for the development of a disease-specific health-related quality of life instrument Fatigue, pain, cognitive difficulties, and mental health concerns were recurring themes. Until recently, no disease-specific quality-of-life measurement tool even existed for relapsing polychondritis, though one has now been developed and validated.35PubMed Central. Development and validation of a relapsing polychondritis disease-specific quality of life instrument (ERN ReCONNET RP-QoL)
Pregnancy and Relapsing Polychondritis
For women of childbearing age, the question of whether pregnancy is safe with relapsing polychondritis comes up often and the data, while limited, are somewhat reassuring. The largest published series tracked 25 pregnancies across 11 patients. Disease flares occurred in seven of the 24 pregnancies that were closely followed, but most were manageable and required treatment changes in only two cases. Fourteen pregnancies were entirely uneventful, and 18 healthy children were born. Complications included ectopic pregnancy, spontaneous miscarriage, and premature birth, but these rates were not dramatically different from those seen in other autoimmune conditions.36PubMed. Pregnancy in relapsing polychondritis: twenty-five pregnancies in eleven patients
An important caveat applies to women with airway involvement. Pregnancy-related tissue swelling and the medications sometimes used in obstetric emergencies can worsen airway collapse. A case report described a patient with tracheobronchial disease who developed severe preeclampsia; treatment with magnesium sulfate, a standard preeclampsia drug, worsened her airway collapse and triggered acute respiratory failure.37PubMed Central. Management of preeclampsia with severe features in a patient with relapsing polychondritis affecting the tracheobronchial tree For patients whose airways are already compromised, pregnancy planning with a multidisciplinary team is essential.
When It Starts in Childhood
Relapsing polychondritis in children is exceedingly rare, and most of what we know comes from case reports rather than large studies. A systematic review pooling 68 pediatric cases found a mean age of onset of 12 years, with a female predominance of about 65%. The median delay to diagnosis was one year, which is actually somewhat faster than in adults, possibly because ear and nose symptoms in a child prompt earlier suspicion of something unusual.38PubMed. Systematic Literature Review of the Presentation and Management of Pediatric Relapsing Polychondritis
The presentation in children looks broadly similar to adults but with a striking difference: respiratory tract involvement was reported in 63% of pediatric cases, much higher than the 20 to 50% typically cited for adults. Tracheostomy was needed in 38% of the pediatric cases reviewed, a sobering figure. Corticosteroids were used in 91% of children, and methotrexate in 35%. Among the smaller number treated with monoclonal antibodies (most often infliximab), 87% responded, suggesting biologics may be particularly useful in severe pediatric disease.39PubMed. Systematic Literature Review of the Presentation and Management of Pediatric Relapsing Polychondritis The rarity of pediatric cases means that every treatment decision is essentially a judgment call informed by adult experience and individual response rather than by dedicated pediatric trial data.